tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

PTC Therapeutics resumed with Buy from Neutral at UBS

UBS upgraded PTC Therapeutics to Buy from Neutral with a $47 price target after resuming coverage of the name. With multiple new drug application filings this year and potential commercial launches next year along with upcoming clinical catalysts, there is upside potential for the shares, the analyst tells investors in a research note. The firm thinks investor focus on Translarna headwinds following the surprising removal from the European Union market has left many of PTC’s pipeline programs underappreciated at current levels. UBS sees upside into the potential phenylketonuria approval and launch in 2025.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1